ABBV-368

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported.

Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported.

Maximum Serum Concentration (Cmax) of ABBV-368

Maximum Observed Plasma Concentration (Cmax) of Tilsotolimod

Maximum Observed Serum Concentration (Cmax) of ABBV-181

Time to Maximum Serum Concentration (Tmax) of ABBV-181

Area Under Serum Concentration-Time Curve of ABBV-181 From Time 0 to the Time of Last Measurable Concentration (AUCt)

Terminal-Phase Elimination Rate Constant (β) of ABBV-181

Terminal Half-Life (t1/2) of ABBV-181

Area under the serum concentration-time curve of ABBV-368

The MTD of ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181 will be determined during the dose escalation phase of the study.

Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181 will be established during the Dose expansion of the study

Time to Cmax of ABBV-368

Terminal phase elimination rate constant of ABBV-368

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.